143 related articles for article (PubMed ID: 24919623)
1. Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.
Muzic JG; Kindle SA; Tollefson MM
JAMA Dermatol; 2014 Sep; 150(9):1024-5. PubMed ID: 24919623
[No Abstract] [Full Text] [Related]
2. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
Nathan N; Wang JA; Li S; Cowen EW; Haughey M; Moss J; Darling TN
J Am Acad Dermatol; 2015 Nov; 73(5):802-8. PubMed ID: 26365597
[TBL] [Abstract][Full Text] [Related]
3. Familial multiple discoid fibromas: unique histological features and therapeutic response to topical rapamycin.
Wee JS; Chong H; Natkunarajah J; Mortimer PS; Moosa Y
Br J Dermatol; 2013 Jul; 169(1):177-80. PubMed ID: 23495951
[TBL] [Abstract][Full Text] [Related]
4. Fibrous Cephalic Plaque in Tuberous Sclerosis Complex: Treatment With 0.2% Rapamycin.
Giacaman A; Martín-Santiago A
Actas Dermosifiliogr (Engl Ed); 2019 Jun; 110(5):e13. PubMed ID: 30846165
[No Abstract] [Full Text] [Related]
5. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
[TBL] [Abstract][Full Text] [Related]
6. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
7. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
Leducq S; Giraudeau B; Tavernier E; Maruani A
J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
[TBL] [Abstract][Full Text] [Related]
8. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
[TBL] [Abstract][Full Text] [Related]
10. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
Tu J; Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
12. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
Mutizwa MM; Berk DR; Anadkat MJ
Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
[No Abstract] [Full Text] [Related]
13. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy.
Park J; Yun SK; Cho YS; Song KH; Kim HU
Dermatology; 2014; 228(1):37-41. PubMed ID: 24401865
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the Future.
Arbiser JL
JAMA Dermatol; 2015 Jul; 151(7):703-4. PubMed ID: 25692853
[No Abstract] [Full Text] [Related]
15. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
Wheless JW; Almoazen H
J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
[TBL] [Abstract][Full Text] [Related]
16. Koenen tumors in tuberous sclerosis: a review and clinical considerations for treatment.
Liebman JJ; Nigro LC; Matthews MS
Ann Plast Surg; 2014 Dec; 73(6):721-2. PubMed ID: 25397697
[TBL] [Abstract][Full Text] [Related]
17. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex.
Koenig MK; Butler IJ; Northrup H
J Child Neurol; 2008 Oct; 23(10):1238-9. PubMed ID: 18952591
[TBL] [Abstract][Full Text] [Related]
18. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
[TBL] [Abstract][Full Text] [Related]
19. Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas.
Bouguéon G; Lagarce F; Martin L; Pailhoriès H; Bastiat G; Vrignaud S
Int J Pharm; 2016 Jul; 509(1-2):279-284. PubMed ID: 27260135
[TBL] [Abstract][Full Text] [Related]
20. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
Rauktys A; Lee N; Lee L; Dabora SL
BMC Dermatol; 2008 Jan; 8():1. PubMed ID: 18226258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
